BCL2L1 and cancer: Having validated WEHI-539 as a valuable research tool to probe Bcl-xL function in the context of mitotic cell fate, we set out to determine whether it sensitized cancer cells to various mitotic blockers, initially focusing on the microtubule-binding agents taxol and nocodazole.